A look at the shareholders of Qiagen N.V. (NYSE:QGEN) can tell us which group is most powerful. The group holding the most number of shares in the company, around 82% to be precise, is institutions.

Parse Biosciences co-founders are CTO Charles Roco and CEO Alex Rosenberg. (Parse Photo) Seattle’s Parse Biosciences is teed up for an acquisition by Qiagen, a Netherlands-based holding company, in a ...

Qiagen Chief Executive Thierry Bernard plans to step down from the biotechnology provider. Bernard has been chief executive for six years and will resign after a successor is appointed, the ...

The news is coming thick and fast for Qiagen. As the molecular diagnostics specialist announced its third-quarter earnings, it also revealed that its long-term chief executive, Thierry Bernard, will ...

Acquisition strengthens QIAGEN’s presence in the rapidly growing single-cell market, accelerating growth across its industry-leading Sample technologies portfolio Parse provides Evercode, a highly ...

Q3 2025 results: Net sales of $533 million (+6% at actual rates); diluted EPS $0.60 Core sales +6% CER (constant exchange rates) driven by QIAstat-Dx (+11% CER), QuantiFERON (+11% CER) and Sample ...

The Federal Circuit recently reversed a $4.7M verdict in a patent lawsuit involving two patents concerning next-generation sequencing methods—U.S. Patent Nos. 10,017,810 and 10,450,597. Both patents ...

Fintel reports that on June 24, 2025, Barclays initiated coverage of Qiagen N.V. (NYSE:QGEN) with a Overweight recommendation. Analyst Price Forecast Suggests 6.68% Upside As of June 20, 2025, the ...

The new partnership combines QIAGEN’s QIAcuityDx digital PCR platform to advance sensitive, cost-effective oncology diagnostics with GENCURIX’s expertise in multiplex assay development. The aim is to ...

Activist Commentary: Fivespan Partners, LP is a San Francisco-based investment firm founded by Dylan Haggart and Sarah Coyne. Prior to Fivespan, Haggart and Coyne were partners at ValueAct Capital and ...